4//SEC Filing
Cieplinska Agnieszka 4
Accession 0001179110-20-010054
CIK 0001235010other
Filed
Sep 30, 8:00 PM ET
Accepted
Oct 1, 5:01 PM ET
Size
19.0 KB
Accession
0001179110-20-010054
Insider Transaction Report
Form 4
Cieplinska Agnieszka
Chief Accounting Officer (PAO)
Transactions
- Disposition to Issuer
Stock Options (Right to Buy)
2020-10-01−22,845→ 0 totalExercise: $13.85Exp: 2029-04-12→ Common Stock (22,845 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−3,641→ 0 totalExercise: $31.87Exp: 2030-02-07→ Common Stock (3,641 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−2,155→ 0 totalExercise: $13.85Exp: 2029-04-12→ Common Stock (2,155 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-10-01−12,672→ 0 totalExercise: $31.87Exp: 2030-02-07→ Common Stock (12,672 underlying) - Disposition to Issuer
Restricted Stock Units
2020-10-01−9,450→ 0 total→ Common Stock (9,450 underlying) - Disposition to Issuer
Common Stock
2020-10-01−8,136→ 0 total - Disposition to Issuer
Restricted Stock Units
2020-10-01−8,193→ 0 total→ Common Stock (8,193 underlying)
Footnotes (4)
- [F1]Includes 425 shares and 137 shares acquired under the Issuer's employee stock purchase plan respectively on July 31, 2020 and September 28, 2020.
- [F2]Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of August 19, 2020 (the "Merger Agreement"), by and among Johnson & Johnson, Vigor Sub, Inc. ("Merger Sub") and the Issuer, including the completion of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $52.50 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Merger Sub on October 1, 2020. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
- [F3]Reflects disposition of Issuer restricted stock units in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer restricted stock unit held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer restricted stock unit immediately prior to the Effective Time by (y) the Offer Price.
- [F4]Reflects disposition of options to acquire shares of Issuer common stock (each, an "Issuer Option") in accordance with the Merger Agreement, pursuant to which, effective immediately prior to the Effective Time, each Issuer Option held by the Reporting Person became vested in full and, as of the Effective Time, was cancelled and converted into the right to receive an amount in cash (without interest) equal to the product obtained by multiplying (x) the aggregate number of shares of Issuer common stock underlying such Issuer Option immediately prior to the Effective Time by (y) the amount, if any, by which the Offer Price exceeds the per share exercise price of such Issuer Option.
Documents
Issuer
MOMENTA PHARMACEUTICALS INC
CIK 0001235010
Entity typeother
Related Parties
1- filerCIK 0001798748
Filing Metadata
- Form type
- 4
- Filed
- Sep 30, 8:00 PM ET
- Accepted
- Oct 1, 5:01 PM ET
- Size
- 19.0 KB